2026 | Revive Therapeutics

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

by rvvadmin | Aug 12, 2026 | 2026

TORONTO, ON – August 12, 2026 / Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic...

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

by rvvadmin | Jul 15, 2026 | 2026

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON – July 15, 2026 / Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company...

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

by rvvadmin | May 20, 2026 | 2026

Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling TORONTO, ON / May...

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

by rvvadmin | Mar 11, 2026 | 2026

Patent momentum expands Revive’s bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / March 11, 2026 / Revive Therapeutics Ltd. (“Revive” or the...